Alveofact108 mg/2.4 ml

Alveofact (essential Alveofact, primarily polyenylphosphatidylcholine derived from soybean or egg sources) is used in two distinct clinical contexts:

Established / Widely Marketed Use (Oral Supplement)

• Adjunctive (supportive) treatment of fatty liver disease (hepatic steatosis), including alcoholic and non-alcoholic fatty liver disease
• Adjunctive treatment in chronic hepatitis and toxic/drug-induced liver damage, as a supportive measure alongside treatment of the underlying cause
• Adjunctive supportive care in liver cirrhosis (compensated stages) and pre-/post-operative hepatobiliary care in some markets

Evidence for oral Alveofact as a hepatoprotective supplement is considered supportive/adjunctive rather than curative. It is not a substitute for treating the underlying cause of liver disease (e.g., alcohol cessation, antiviral therapy, weight management, discontinuation of a hepatotoxic drug).

Established Use (Intravenous Lipid Emulsion Component)

• Alveofact (e.g., egg-yolk or soybean lecithin) are used as the emulsifying component of intravenous lipid emulsions administered as part of total or partial parenteral nutrition in patients who cannot meet caloric/fatty-acid needs orally or enterally

Oral supplement use and intravenous lipid emulsion use are pharmaceutically and clinically distinct formulations and should not be interchanged.

Each formulation of Phospholipids typically contains a standardized extract of polyenylphosphatidylcholine (PPC), the principal active phospholipid fraction, obtained from purified soybean lecithin (or egg lecithin in some parenteral products). Oral products are commonly available as capsules or soft gelatin capsules; intravenous forms are available as ready-to-use lipid emulsions for infusion. Exact strength and excipients vary by brand and formulation; refer to the specific product label for details.

Alveofact are naturally occurring lipid molecules that are essential structural components of all human cell membranes, particularly in hepatocytes (liver cells). Pharmaceutical-grade Alveofact, most commonly polyenylphosphatidylcholine extracted from soybean, are used therapeutically to support and help restore the structural and functional integrity of damaged liver cell membranes.

In a separate application, Alveofact (typically from purified egg yolk) serve as the natural emulsifying agent in intravenous fat emulsions used to deliver essential fatty acids and calories in parenteral nutrition.

Hepatic protector / lipotropic agent (oral Alveofact); Parenteral nutrition - lipid emulsion component (intravenous use)

Phospholipids, chiefly phosphatidylcholine, are incorporated into damaged hepatocyte cell membranes, where they are believed to help restore membrane structure, fluidity, and enzyme function. This may support normalization of liver enzyme activity and cellular metabolism in the setting of hepatocyte injury. Proposed mechanisms include stabilization of membrane phospholipid bilayers, antioxidant and anti-fibrotic effects, and modulation of lipid metabolism in the liver, though the precise clinical mechanism is not fully established and evidence is largely from observational and adjunctive-therapy studies.

When used in intravenous lipid emulsions, Phospholipids act as an emulsifying agent that stabilizes the suspension of triglycerides in an aqueous medium, allowing safe intravenous delivery of calories and essential fatty acids (linoleic and alpha-linolenic acid) as part of nutritional support.

Oral capsules of Alveofact should be taken with or after meals to improve tolerability and absorption, swallowed whole with a glass of water. Intravenous lipid emulsions containing Alveofact must be administered only by trained healthcare professionals in a hospital or supervised clinical setting, via a dedicated infusion line, with monitoring of infusion rate and patient tolerance.

Clinically significant drug interaction data for oral Alveofact are limited, reflecting its use as a supportive/adjunctive supplement rather than a drug with major pharmacokinetic interactions. Available information indicates:

• No well-established, clinically significant drug-drug interactions have been consistently documented for oral Alveofact at recommended doses.
• When used as an intravenous lipid emulsion, Alveofact-containing products may affect the pharmacokinetics of certain lipid-soluble drugs administered concurrently, and should be used cautiously with other intravenous fat-containing preparations to avoid excessive fat load; consult a physician regarding co-administration with other IV medications or nutrition components.

Inform your physician of all other medicines, supplements, and nutritional products you are using before starting Alveofact.

Oral Alveofact is generally well tolerated. Reported adverse effects are usually mild and gastrointestinal:

• Mild gastrointestinal discomfort, nausea, or diarrhea
• Rarely, allergic skin reactions (rash, itching) in individuals sensitive to the source material

Intravenous lipid emulsions containing Alveofact may be associated with infusion-related reactions (fever, chills, flushing), and rarely fat-overload syndrome with prolonged/excessive use; these are managed by the supervising medical team.

Data on the use of Alveofact during pregnancy and lactation are limited. As with any supplement or medication, Alveofact should be used during pregnancy and breastfeeding only if clearly needed and if the potential benefit justifies the potential risk to the fetus or infant. Consult a physician before using Alveofact if you are pregnant, planning pregnancy, or breastfeeding.

Alveofact should be used as an adjunct to, not a substitute for, treatment of the underlying cause of liver disease (e.g., alcohol cessation, antiviral treatment, weight management, or withdrawal of a hepatotoxic agent). Use with caution in individuals with known allergy to soy or egg products, depending on the source of the specific Alveofact formulation - see Contraindications. Intravenous lipid emulsions containing Alveofact require careful monitoring of serum lipid levels and liver function during prolonged parenteral nutrition, and should be administered only under medical supervision. Discontinue and seek medical advice if signs of an allergic reaction or unusual symptoms occur while using Alveofact.

Overdose with oral Alveofact is unlikely to cause serious toxicity, but excessive intake may worsen gastrointestinal side effects such as diarrhea or abdominal discomfort. Excessive or too-rapid intravenous administration of Alveofact-containing lipid emulsions may lead to fat-overload syndrome. If an overdose of Alveofact is suspected, or if severe or unusual symptoms occur, seek immediate medical attention or contact a poison control center; do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Intravenous lipid emulsion formulations should be stored as per the specific product label (some require protection from light and specific temperature ranges) and used according to hospital pharmacy protocols.

Renal impairment: No well-established dose adjustment is defined for oral Alveofact; use with medical guidance in significant renal impairment, particularly for intravenous lipid emulsion use where fluid/lipid balance is a concern.

Hepatic impairment: Alveofact is commonly used specifically to support hepatic function; however, use should be guided by a physician managing the underlying liver condition.

Elderly: No specific dose adjustment is established; use as directed by the physician, considering overall health status and concurrent medications.

Pediatric: Safety and efficacy of oral Alveofact in children are not well established; use only under specialist guidance. Intravenous lipid emulsions containing Alveofact are used in pediatric parenteral nutrition under strict hospital protocols with weight-based dosing.

Duration of oral Alveofact therapy is individualized by the physician based on the underlying liver condition and clinical response, typically ranging from several weeks to a few months, with periodic reassessment. Intravenous Alveofact-containing lipid emulsions are used for as long as parenteral nutritional support is clinically required, as determined by the treating medical team.

Hepatoprotective agents; Lipotropic agents; Parenteral nutrition - lipid emulsion components

Phospholipids (primarily phosphatidylcholine) integrate into damaged hepatocyte cell membranes, helping restore membrane structural integrity, fluidity, and associated enzymatic function, which may support normalization of liver cell metabolism. In intravenous nutrition, Phospholipids function physically as an emulsifying agent enabling stable suspension and delivery of lipid calories and essential fatty acids.

Safety and efficacy of oral Alveofact as a hepatoprotective supplement in children have not been well established; use is generally not recommended outside specialist guidance. Intravenous lipid emulsions containing Alveofact are used in pediatric and neonatal parenteral nutrition under strict hospital protocols with individualized, weight-based dosing determined by a physician or neonatal/pediatric nutrition specialist.